Prognosis of Clinical Stage ⅢA(N2) Non-small Cell Lung Cancer Patients Received Ming, QIAO Xueying
-
摘要:目的
探讨临床分期为ⅢA（N2）期非小细胞肺癌放射治疗的预后及其影响因素。
方法收集2010年1月—2011年12月于河北医科大学第四医院接受放射治疗的临床分期为ⅢA（N2）期非小细胞肺癌患者共113例，观察临床疗效，并分析预后影响因素。
结果全组1、2、3年生存率分别为70.5%、39.3%、23.8%；1、2、3年局部控制率分别为76.6%、54.5%、47.9%；1、2、3年无病生存率分别为50.6%、25.3%、18.7%。单因素分析显示，性别、ECOG评分、是否化疗和近期疗效与总生存率有关；T分期、GTV大小、是否化疗和近期疗效与局部控制率有关。多因素分析显示，性别、ECOG评分、是否化疗和近期疗效是影响总生存率的独立预后因素，GTV大小、是否化疗和近期疗效是影响局部控制率的独立预后因素。全组≥2级放射性肺炎15例，占13.3%；≥2级放射性食管炎6例，占5.3%；≥2级血液学不良反应20例，占17.7%。
结论放射治疗在临床分期为ⅢA（N2）期非小细胞肺癌中疗效确切，不良反应可耐受。性别、ECOG评分、GTV大小、是否化疗和近期疗效为ⅢA（N2）期NSCLC患者预后的主要影响因素。
Abstract:ObjectiveTo investigate the efficacy and prognostic factors of clinical stage ⅢA(N2) non-smallcell lung cancer (NSCLC) patients treated with 3-dimensional conformal or intensity-modulated radiotherapy.
MethodsFrom January 2010 to December 2011, the data of 113 patients with clinical stage ⅢA(N2) NSCLC at the Fourth Hospital of Hebei Medical University were analyzed. The efficacy and prognosticfactors were observed.
ResultsThe overall 1-, 2- and 3-year overall survival (OS) of entire cohort were70.5%, 39.3% and 23.8%, respectively. The overall 1-, 2- and 3-year local control rates(LCR) of entirecohort were 76.6%, 54.5% and 47.9%, respectively. The overall 1-, 2- and 3-year disease-free survival (DFS)of entire cohort were 50.6%, 25.3% and 18.7%, respectively. The univariate analysis showed that gender,ECOG performance status, chemotherapy and tumor response were associated with OS; T stage, GTV size,chemotherapy and tumor response were associated with LCR. Multivariate analysis revealed that gender,ECOG performance status, chemotherapy and tumor response were the independent factors for predicting theOS; GTV size, chemotherapy and tumor response were the independent factors for predicting the LCR. There were 13.3% (15/113) patients with grade≥2 acute radiation-related pneumonitis after radiotherapy; there were 5.3% (6/113) patients with grade≥2 acute radiation esophagitis; there were 17.7% (20/113) patients with grade≥2 hematologic toxicity.
ConclusionRadiotherapy may be effective in the treatment of clinicalstage ⅢA(N2) NSCLC and side-effect can be tolerated. Gender, ECOG performance status, GTV size,chemotherapy and tumor response may be the independent risk factors for predicting the prognosis.
-
Key words:
- Non-small cell lung cancer /
- Radiotherapy /
- Survival /
- Prognostic factors
-
-
表 1 113例ⅢA(N2)期非小细胞肺癌患者影响总生存率和 局控率的单因素分析结果
Table 1 Prognostic factors for OS and LCR of 113 ⅢA(N2) NSCLC patients by univariate analysis
下载: 导出CSV
表 2 113例ⅢA(N2)期非小细胞肺癌患者影响总生存率的多因素分析
Table 2 Prognostic factors for OS of 113 ⅢA(N2) NSCLC patients by multivariate analysis
下载: 导出CSV
表 3 113例ⅢA(N2)期非小细胞肺癌患者影响局部控制率的多因素分析
Table 3 Prognostic factors for LCR of 113 ⅢA(N2) NSCLC patients by multivariate analysis
下载: 导出CSV
-
[1] Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J].CA Cancer J Clin, 2014, 64(1): 9-29.
[1] Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29. [2] Aggarwal C, Li L, Borghaei H, et al. Multidisciplinary therapy of stage ⅢA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgery[J]. Cancer Control, 2014,21(1): 57-62.
[2] Aggarwal C, Li L, Borghaei H, et al. Multidisciplinary therapy of stage ⅢA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgery[J]. Cancer Control, 2014, 21 (1): 57-62. [3] 张连民, 刘喜增,张真发, 等. ⅢA-N2期非小细胞肺癌切除术后影响预后的因素分析[J]. 中华外科杂志, 2010, 48(9): 690-3. Zhang LM, Liu XZ, Zhang ZF, et al. A clinical and prognostic retrospective analysis of ⅢA-N2 non-small cell lung cancer[J].Zhonghua Wai Ke Za Zhi, 2010, 48(9): 690-3.
[3] Zhang LM, Liu XZ, Zhang ZF, et al. A clinical and prognostic retrospective analysis of ⅢA-N2 non-small cell lung cancer[J]. Zhonghua Wai Ke Za Zhi, 2010, 48(9): 690-3. [张连民, 刘喜增, 张真发, 等. ⅢA-N2期非小细胞肺癌切除术后影响预后的因素 分析[J] 中华外科杂志, 2010, 48(9): 690-3.] [4] Ma Q, Liu D, Guo Y, et al. Surgical therapeutic strategy for nonsmall cell lung cancer with mediastinal lymph node metastasis (N2) [J]. Zhongguo Fei Ai Za Zhi, 2010, 13(4): 342-8. [4] Ma Q, Liu D, Guo Y, et al. Surgical therapeutic strategy for nonsmall cell lung cancer with mediastinal lymph node metastasis(N2)[J]. Zhongguo Fei Ai Za Zhi, 2010, 13(4): 342-8.
[5] Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage Ⅲ nonsmall- cell lung cancer: a phase Ⅲ randomised controlled trial[J]. Lancet, 2009, 374(9687): 379-86. [5] Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage Ⅲ nonsmall-cell lung cancer: a phase Ⅲ randomised controlled trial[J].Lancet, 2009, 374(9687): 379-86.
[6] Zhu XZ, Wang LH, Ou GF, et al. Prognosis of locally advanced non small cell lung cancer treated with three dimentional conformal radiotherapy[J]. Zhonghua Zhong Liu Za Zhi, 2007, 29 (10): 748-53. [朱向帜, 王绿化, 欧广飞, 等. 三维适形放射 治疗局部晚期非小细胞肺癌预后因素分析[J]. 中华肿瘤杂志, 20 07, 29(10): 748-53.] [6] 朱向帜, 王绿化, 欧广飞, 等. 三维适形放射治疗局部晚期非小细胞肺癌预后因素分析[J]. 中华肿瘤杂志,2007, 29(10): 748-53. Zhu XZ, Wang LH, Ou GF, et al. Prognosis of locally advanced non small cell lung cancer treated with three dimentional conformal radiotherapy[J]. Zhonghua Zhong Liu Za Zhi, 2007,29(10): 748-53.
[7] Laine AM, Westover KD, Choy H, et al. Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer[J]. Semin Oncol, 2014, 41(1): 57-68. [7] Laine AM, Westover KD, Choy H, et al. Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer[J]. Semin Oncol, 2014, 41(1): 57-68.
[8] Wang L, Correa CR, Zhao L, et al. The effect of radiation dose and chemotherapy on overall survival in 237 patients with stage Ⅲ non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys. 20 09, 73(5): 1383-90. [8] Wang L, Correa CR, Zhao L, et al. The effect of radiation dose and chemotherapy on overall survival in 237 patients with stage Ⅲ non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys.2009, 73(5): 1383-90.
[9] Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010,28(13): 2181-90.
[9] Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28 (13): 2181-90. [10] McGovern SL, Liao Z, Bucci MK, et al. Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer?[J]. Cancer, 2009, 115(14): 3233-42.
[10] McGovern SL, Liao Z, Bucci MK, et al. Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer?[J]. Cancer, 2009, 115(14): 3233-42. [11] Basaki K, Abe Y, Kondo H, et al. Prognostic factors for survival in Stage Ⅲ non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume[J]. Int J Radiat Oncol Biol Phys, 2006, 64(2): 449-54.
[11] Basaki K, Abe Y, Kondo H, et al. Prognostic factors for survival in Stage Ⅲ non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume[J]. Int J Radiat Oncol Biol Phys, 2006, 64(2): 449-54. [12] Kwan HC, Sung JA, Hong RP, et al. A phase Ⅱ study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage Ⅲ nonsmall-cell lung cancer: results of Korean Radiation Oncology Group 0301 study[J]. Int J Radiat Oncol Biol Phys, 2009, 74(5):1397-404.
[12] Kwan HC, Sung JA, Hong RP, et al. A phase Ⅱ study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage Ⅲ nonsmall- cell lung cancer: results of Korean Radiation Oncology Group 0301 study[J]. Int J Radiat Oncol Biol Phys, 2009, 74(5): 13 97-404. [13] 王静, 乔学英, 贾敬好, 等. 局部晚期非小细胞肺癌累及野三维适形放疗的预后分析[J]. 肿瘤防治研究, 2011, 38(2):195-8. Wang J, Qiao XY, Jia JH, et al. Prognosis of three dimensional conformal radiotherapy of locally advanced non-small cell lung cancer with involved-field[J]. Cancer Res Prev Treat, 2011, 38(2):195-8.
[13] Wang J, Qiao XY, Jia JH, et al. Prognosis of three dimensional conformal radiotherapy of locally advanced non-small cell lung cancer with involved-field[J]. Cancer Res Prev Treat, 2011, 38(2): 19 5-8. [王静, 乔学英, 贾敬好, 等. 局部晚期非小细胞肺癌累 及野三维适形放疗的预后分析[J]. 肿瘤防治研究, 2011, 38(2): 19 5-8.] [14] Lee DS, Kim YS, Kang JH, et al. Clinical responses and prognostic indicators of concurrent chemoradiation for non-small cell lung cancer[J]. Cancer Res Treat, 2011, 43(1): 32-41.
[14] Lee DS, Kim YS, Kang JH, et al. Clinical responses and prognostic indicators of concurrent chemoradiation for non-small cell lung cancer[J]. Cancer Res Treat, 2011, 43(1): 32-41. [15] Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage ⅢA or ⅢB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study[J]. Lancet Oncol, 2015, 16(2): 187-99. [15] Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage ⅢA or ⅢB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study[J]. Lancet Oncol, 2015, 16(2): 187-99.
计量
- 文章访问数: 1284
- HTML全文浏览量: 367
- PDF下载量: 577
